GSK plc Stock Deutsche Boerse AG

Equities

GS71

GB00BN7SWP63

Pharmaceuticals

Market Closed - Deutsche Boerse AG 03:41:18 2024-04-26 pm EDT 5-day change 1st Jan Change
19.15 EUR +0.52% Intraday chart for GSK plc +3.79% +14.78%

Financials

Sales 2024 * 31.48B 39.29B 36.73B Sales 2025 * 33.38B 41.66B 38.95B Capitalization 67.54B 84.31B 78.82B
Net income 2024 * 5.66B 7.07B 6.61B Net income 2025 * 6.4B 7.98B 7.47B EV / Sales 2024 * 2.53 x
Net Debt 2024 * 12.17B 15.19B 14.2B Net Debt 2025 * 8.93B 11.15B 10.42B EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
11.9 x
P/E ratio 2025 *
10.6 x
Employees 70,212
Yield 2024 *
3.68%
Yield 2025 *
3.92%
Free-Float 92.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.52%
1 week+3.79%
Current month-3.51%
1 month-2.06%
3 months+7.58%
6 months+16.06%
Current year+14.78%
More quotes
1 week
18.45
Extreme 18.45
19.62
1 month
18.23
Extreme 18.23
19.83
Current year
16.48
Extreme 16.482
20.12
1 year
15.24
Extreme 15.242
20.12
3 years
14.62
Extreme 14.62
27.13
5 years
14.62
Extreme 14.62
27.52
10 years
14.62
Extreme 14.62
28.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 10-04-30
Director of Finance/CFO 62 23-04-30
Compliance Officer - 95-07-31
Members of the board TitleAgeSince
Director of Finance/CFO 62 23-04-30
Chairman 66 19-08-31
Director/Board Member 65 14-12-31
More insiders
Date Price Change Volume
24-04-26 19.15 +0.52% 400
24-04-25 19.05 +1.87% 3,643
24-04-24 18.7 -1.66% 647
24-04-23 19.02 +1.01% 278
24-04-22 18.82 +2.03% 116

Delayed Quote Deutsche Boerse AG, April 26, 2024 at 03:41 pm EDT

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.53 GBP
Average target price
20.06 GBP
Spread / Average Target
+21.34%
Consensus